

RESEARCH INKlings

July 2003 • Medical University of South Carolina • Volume XII • No. 7

NIH Study Sections get names and initials

In response to requests from applicants, reviewers, members of working groups, and others the Center for Scientific Review (CSR) has designated descriptive names and acronyms for study sections that previously were identified only by the Integrated Review Group (IRG) title and a number. For example, "Brain Disorders and Clinical Neuroscience Study Section 3" (BDCN-3) is now "Cell Death and Injury in Neurodegeneration Study Section" (CDIN). These names/acronyms are being used for applications received on or after May 1, 2003.

The following IRGs are involved:

- AIDS and Related Research (AARR)
- Behavioral and Biobehavioral Processes (BBBP)
- Health of the Population (HOP) formerly Social Sciences, Nursing, Epidemiology and Methods (SNEM)
- Risk Prevention and Health Behavior (RPHB)
- Brain Disorders and Clinical Neuroscience (BDCN)
- Integrative, Functional, and Cognitive Neuroscience (IFCN)
- Molecular, Cellular, and Developmental Neuroscience (MDCN)

Reviewer membership and the review focus of these IRGs and their study sections have not changed. If the name/acronym in the notification of assignment or change of assignment letter is unfamiliar, check the following url <<http://www.csr.nih.gov/>>.

Source: *NIH Guide*, week ending June 6, 2003

SC Research Universities Seek Freedom From State Controls

Faced with dwindling state appropriations, public research universities in SC recently sought more control over their financial affairs during this year's legislative session. Clemson University, MUSC, and USC requested independence from the state's higher-education governing board, the SC Commission on Higher Education, in order to work with private businesses to spur economic development in the state. The universities wanted to abolish the commission and create a new governing council that would have been run mostly by their own trustees. The institutions also desired regulatory changes to simplify procurement practices and to permit them to enter into land-lease agreements with private companies, allowing the businesses to build on state-owned land. The state commission, public regional universities, and two-year colleges in SC opposed these efforts, voicing concerns that the universities, having their own governing councils, would destroy checks and balances in state government that make sure postsecondary institutions respond to the interests of taxpayers. A spokesman for the SC Commission on Higher Education stated that having the Commission oversee all state institutions helps avoid unnecessary duplication of academic programs, makes transfer policies smoother, and coordinates efforts to improve SC resident's access to college. Furthermore, the commission suggested that research universities, acting on their own, would probably gain more political power than other institutions, and that keeping all institutions under one umbrella helps protect regional universities and community colleges, and leads to a fairer distribution of state funds among all institutions

Source: *Chronicle of Higher Education—Government & Politics—Volume 49, Issue 41, Page A19*



FDA Approves First Biologic for Allergy-Related Asthma

The Food and Drug Administration (FDA) recently approved the first biotechnology product to treat patients with allergy-related asthma. The product, omalizumab (Xolair), is a monoclonal antibody that has been shown to be safe and effective to treat people with moderate to severe allergy-related asthma inadequately controlled with inhaled steroid treatments. Given as a subcutaneous injection, omalizumab has been shown to decrease the number of asthma exacerbations or episodes of airway narrowing that result in wheezing, breathlessness, and cough. Asthma is an airway disease affecting approximately 17 million in the US; it is estimated that a relatively small percentage of these people would be appropriate candidates for this second-line treatment, which would be recommended only after first-line treatments have failed. Omalizumab is a genetically engineered protein that blocks the immune cascade that normally occurs in response to allergens. Omalizumab is manufactured by Genentech, San Francisco, CA. Genentech will jointly market the product in conjunction with Novartis Pharmaceutical Corp., East Hanover, NJ.

Source: *FDA News*—June 20, 2003 



FDA Approves Prilosec OTC to Treat Frequent Heartburn

The Food and Drug Administration (FDA) today announced the approval of Prilosec OTC (omeprazole), the first over-the-counter treatment for frequent heartburn. Omeprazole, a proton pump inhibitor, is indicated for the treatment of heartburn that occurs two or more days per week. Prescription omeprazole is currently available for frequent heartburn and other related, but more serious, problems that need a physician's care. FDA based its approval of omeprazole OTC on the results of efficacy studies. Prescription omeprazole, first approved by FDA in 1989, will remain available as a prescription treatment (but in the same dose as the OTC product) for diseases that require diagnosis and supervision by a doctor, such as gastroesophageal reflux disease, inflammation of the esophagus, and ulcers. This product will have three years of over-the-counter exclusivity, and generic versions of the prescription product will be ineligible to market an OTC version until the exclusivity has expired. AstraZeneca LP of Wilmington, DE, and Procter and Gamble of Cincinnati, OH, are the sponsors of the approved New Drug Application (NDA) for Prilosec OTC.


Source: *FDA News* □ June 20, 2003 



Giving to Education Declines in 2002

Charitable giving to education declined to \$31.64-billion in 2002, an estimated 1.1-percent reduction and the first annual decrease since consecutive drops in 1974 and 1975, according to the annual *Giving USA* report. Adjusted for inflation, total giving to education in 2002 was 2.6 percent smaller than in 2001, the second straight year of inflation-adjusted declines. In the mid-1970s, when double-digit inflation was rampant, adjusted-giving totals for education fell three straight years, from 1973 through 1975. Factors contributing to the current decline include three years of declining stock values, conflicts abroad, recovery from the terrorist attacks of 2001, and corporate woes involving huge bankruptcies and allegations of criminal conduct.

Over all, Americans gave an estimated \$240.9-billion to charity in 2002, a slight annual increase in total dollars, but an inflation-adjusted decline of less than 1 percent. Educational institutions received about 13 percent of those charitable gifts. Foundations' endowments, a critical source of giving to education, have been decimated by poorly performing capital markets. Total foundation grants to all types of recipients declined to \$26.9-billion in 2002, an inflation-adjusted drop of 2.7 percent.

Source: *Chronicle of Higher Education*, June 23, 2003 - *The Chronicle Online*—*Today's News* 


R E S E A R C H
Opportunities & Deadlines

AGING

Title: Centers on the Demography of Aging
Agency: National Institute on Aging (NIA)
Identification: RFA: AG-04-001
Deadline: Letter of Intent Receipt Date - September 22, 2003; Application Receipt Date - October 22, 2003
Link: <<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-04-001.html>>

The NIA invites applications for Research and Development Center Grants (P30) in the areas of demography and economics of health and aging. NIA invites both new teams of investigators and continuing centers (funded under RFA AG-99-001) to apply. The purpose of these center grants is to support infrastructure and pilot data necessary for research and program development in areas such as development of innovative national and international networks of researchers; recruitment of new researchers into the field; development and enhanced sharing of specialized databases, and rapid application of research results from these databases; and the development of statistical data enclaves for the analysis of large-scale, often-longitudinal, databases with linked administrative data. Scientific initiatives in the demography and economics of health and aging increasingly require integration and collaboration with each other and with allied scientific fields such as genetics, biology, clinical medicine, and epidemiology. Applicants may address several of the topic areas below, redefining, merging, and combining topics according to their own perspectives of the future course of the population sciences related to aging. Wherever possible, special attention should be given to the demographic and economic aspects of the health and well-being of special older populations such as the oldest old, Blacks and Hispanics, and older women. Topic areas: Biodemography of Aging; Trends in Chronic Disease and Disability; Health Systems; Living Arrangements; Race, Ethnicity and Socioeconomic Status; Policy Simulations; Work and Retirement; and Disease-Specific General Demography. ▼


AIDS

Title: Novel HIV Therapies: Integrated Preclinical/Clinical Program
Agency: National Institute of Allergy and Infectious Diseases (NIAID) / National Institute of Mental Health (NIMH)
Identification: PAR-03-138
Deadline: Application Receipt Dates - November 17, 2003; November 17, 2004; November 17, 2005
Link: <<http://grants.nih.gov/grants/guide/pa-files/PAR-03-138.html>>

NIAID and **NIMH** invite applications for the discovery, development, and evaluation of innovative therapies for HIV infection. This PA is designed to assist researchers interested in development of HIV therapeutics to assemble the diverse scientific expertise and ancillary resources needed to translate basic laboratory discoveries to applied entities. In the preclinical area, the PA seeks research on: (1) the development/validation of new therapeutic targets; and (2) the discovery, development, and evaluation of small molecule inhibitors of viral or cellular proteins or pathways critical to HIV replication and/or persistence. The inclusion of animal model studies is encouraged. In the clinical area, the focus is on iterative bench to bedside research to optimize new therapeutic approaches. Pilot clinical studies (10–20 subjects) will provide the means for demonstrating proof-of-concept. Applications may propose: (1) preclinical research exclusively; (2) preclinical research that transitions to clinical research during the award period; or (3) clinical research in the first year of award. Responsive applications will involve creative and original therapeutics research with a goal of moving new treatment concepts to the clinic. To facilitate the latter, applications are required to include at least one component (a research project or core) headed by and derived from the private sector, e.g. a pharmaceutical or biotechnology company. Excluded from this PA is research on targets and approaches already under extensive investigation, topical microbicides to block HIV transmission, non-targeted random screening of potential inhibitors, and

research on AIDS-associated opportunistic pathogens and malignancies. 


Title: Centers Program for Research on HIV/AIDS and Mental Health

Agency: National Institute of Mental Health (NIMH)

Identification: PAR-03-142

Deadline: January 2, 2004; January 2, 2005; January 2, 2006 for all new applications and September 1, 2004; September 1, 2005; September 1, 2006 for competing renewal applications

Link: <<http://grants.nih.gov/grants/guide/pa-files/PA-03-142.html>>

The Center for Mental Health Research on AIDS at NIMH supports research centers that provide core support, via a P30 mechanism, for multi-disciplinary research programs focused on mental health and HIV/AIDS. The purpose of this Centers Program is to improve and expand research by supporting infrastructure for administrative coordination; subject recruitment, tracking, and retention; quality control and assurance procedures; performing laboratory testing; performing statistical analyses; database management; sponsoring training and education; and organizational capacity, in order to provide leadership in the integration of multidisciplinary approaches to HIV/AIDS and mental health research, and to expand and develop information-sharing, expertise, technology, and technology transfer in the institutional and clinical communities. The support of this infrastructure will serve to enhance and extend the effectiveness and public health impact of research related to mental health and HIV/AIDS. 

BEHAVIORAL SCIENCE & MENTAL HEALTH



Title: Women, Gender Differences and Drug Abuse


Agency: National Institute on Drug Abuse (NIDA)

Identification: PA-03-139

Deadline: NIH Standard receipt cycles <<http://grants1.nih.gov/grants/dates.htm>>

Link: <<http://grants.nih.gov/grants/guide/pa-files/PA-03-139.html>>

NIDA, via this PA, encourages gender-based drug abuse research applications (R01, R03, and R21

mechanisms) that explore the mechanisms, origins, and consequences of drug abuse, and that develops and assesses gender-based prevention and treatment interventions and services. It also encourages the study of female-specific issues in all areas of drug abuse. Historically, in drug abuse research, as in other fields of public health research, subjects have largely been male, but emerging findings are establishing the importance of studying issues specific to women and studying male-female differences in all areas of drug abuse research. Research of interest includes, but is not limited to, the following: Mechanisms and Origins □gender differences in the basic behavioral; Consequences and Impact □laboratory (both human and animal), field, and clinical research; Prevention and Prevention Services □application of gender-specific theories and empirical findings related to drug use; Treatment and Treatment Services □development and testing of theoretically-based drug treatment approaches that address gender-specific issues; HIV/AIDS and Related Infectious Diseases; and cross-cutting issues. 

Title: Women's Mental Health and Sex/Gender Differences Research

Agency: National Institute of Mental Health (NIMH)

Identification: PA-03-143

Deadline: NIH Standard receipt cycles <<http://grants1.nih.gov/grants/dates.htm>>

Link: <<http://grants1.nih.gov/grants/guide/pa-files/PA-03-143.html>>

NIMH invites research grant applications (R01, R21, R03, and R34) on women's mental health and sex/gender differences in mental health across the lifespan. The overall prevalence of mental disorders does not differ between the sexes, but females and males differ in the prevalence and clinical course of specific disorders. However, an increasing body of basic and clinical research also provides evidence of neurobiological sex differences that may predispose a gender to clinical differences in mental disorders. The finding of sex/gender differences in epidemiological, basic, and clinical studies has also increased interest in the application of that knowledge to improving interventions and services for males and females. In recognition of the importance of studying sex/gender differences in health outcomes, NIH has provided guidelines to

researchers for inclusion of women and men in clinical research and for gender analysis of clinical trials outcomes. Through research such as that called for in this PA, NIMH seeks to increase the understanding of the significance of sex/gender differences in mental health outcomes and to assess their significance for mental health prevention, treatment and services. This program announcement identifies three major areas for research emphasis: basic and clinical neuroscience; epidemiology and risk factors; and intervention and services research. ▼

Title: Research on Community Reintegration for People with Psychiatric Disabilities
Agency: National Institute of Mental Health (NIMH)
Identification: PA-03-144
Deadline: NIH Standard receipt cycles <<http://grants1.nih.gov/grants/dates.htm>>
Link: <<http://grants1.nih.gov/grants/guide/pa-files/PA-03-144.html>>

Using the R01, R03, and R21 mechanisms, the NIMH seeks applications for multidisciplinary/translational research, especially mixed-methods research, that will explore (a) the individual, social, and service system conditions necessary for people with psychiatric disabilities to reintegrate into community life; (b) the organizational and service system conditions necessary to enable service providers to facilitate that reintegration; and (c) the effectiveness of rehabilitation strategies and programs in helping socioculturally diverse individuals who have widely varying goals, material and social resources, and clinical needs. This research, typically called “disability” or “psychiatric rehabilitation” research, has historically focused narrowly on the use of services; compliance; symptom reduction; easily assessed criteria of social and vocational success; and cost. The goal of this PA is to encourage researchers to think beyond usual assumptions underlying “psych rehab,” program fidelity, and outcomes assessment, and to encourage a focus on the individuals within and outside rehabilitation programs who must function within personal, organizational, service system, cultural, and societal boundaries to achieve a return to community life. Researchers should expect to change their focus from assessing therapies, skills training, service models, and program fidelity to a focus on research designed to expedite and ease reintegration

into the community. The research should address the social and physical isolation experienced by consumers who need to develop socioculturally meaningful and useful bridges back to valued social roles. It also needs to deal with the regulatory, organizational, and professional barriers that case workers, whether they are licensed social workers or peer providers, experience in trying to do their jobs. ▼

Title: Gene-Environment Interactions Influencing Alcohol-Related Phenotypes and Diseases
Agency: National Institute on Alcohol Abuse and Alcoholism (NIAAA) / National Institute of Environmental Health Sciences (NIEHS)
Identification: PA-03-141
Deadline: NIH Standard receipt cycles <<http://grants1.nih.gov/grants/dates.htm>>
Link: <<http://grants.nih.gov/grants/guide/pa-files/PA-03-141.html>>

The NIAAA is seeking research grant applications (R01, R21) on the role of gene-environment interactions underlying susceptibility to alcohol-related phenotypes, including alcohol dependence, relapse, withdrawal; alcohol-induced organ damage including neurodegeneration, cirrhosis and other liver diseases, pancreatitis, cardiomyopathy, immune disorders, cancers; and alcohol-induced birth defects. This solicitation specifically encourages multidisciplinary approaches to study how environmental conditions, such as chemical, infectious, physical, nutritional, and social behavioral factors, impact genetic predisposition to alcohol-related diseases. Identification and characterization of gene-environment interactions will offer better opportunities to effectively target prevention, intervention and treatment strategies. NIEHS is collaborating on this PA and is seeking research grant applications on interactions between alcohol effects and environmental agents. NIAAA seeks proposals that will examine environmental factors that alter the epigenetic status of genes that may affect gene expression leading to alcohol-induced diseases. The purpose of this PA is to encourage multidisciplinary research that will investigate gene-environment interactions influencing susceptibility to alcohol abuse and dependence, alcohol-related behaviors, and alcohol-induced organ damage in both animals and humans. ▼

CANCER

Title: Research Grants in Cancer
Agency: Elsa U. Pardee Foundation
Identification: N/A
Deadline: Anytime
Link: <<http://www.pardeefoundation.org/process.htm>>

The Elsa Pardee Foundation has funded an average of 33 new grants per year in the field of cancer research, which is its primary mission. The majority of these new grants support outstanding young research scientists who show considerable promise but who need further research experience before they can gain government funding for their research, government funding being the principal and most substantial source of support for such activity. In general, grants do not provide for building funds, equipment (except that used in a specific project), fellowships or fund-raising campaign contributions. The Foundation particularly welcomes innovative, small-scale, short-term projects which may be difficult to fund elsewhere until some interesting results are obtained. Application forms may be sent in at any time as the Board of Trustees meets periodically to review applications. ▼

HEART, LUNG, & BLOOD DISEASES

Title: American Lung Association Research Awards 2004–2005
Agency: American Lung Association
Identification: N/A
Deadline: September 2, 2003 for all awards
Link: <<http://lungusa.org/research/ran0405.html>>

The American Lung Association invites applications for the following awards:

Research Grants: Seed monies for investigators working in lung science investigating research into the mechanisms of lung disease and general lung biology. Maximum value of grant is \$35,000 US per year for up to two years

Clinical Research Grants: Seed monies for investigators working on traditional clinical studies directly related to patient care, health services, and/or bioethics of lung science. Research areas of particular interest to the American Lung Association are: Psychosocial; Behavioral; Health Services; Health Policy; and Epidemiological and Biostatistical

Matters related to lung disease. Maximum value of grant is \$35,000 US per year for up to two years.

Career investigator: Stable salary and/or project support for investigators making the transition from junior to mid-level faculty. Maximum value of grant is \$50,000 US per year for up to three years.

Lung Health Dissertation Grants: Pre-doctoral support for students with an academic career focus and/or nurses pursuing a doctoral degree. Research areas of particular interest to the American Lung Association are: Psychosocial; Behavioral; Health Services; Health Policy; and Epidemiological and Biostatistical Matters related to lung disease. Maximum value of grant is \$21,000 US per year for up to three years.

Senior Research Training Fellowship: Research areas of particular interest are: Adult Pulmonary Medicine; Pediatric Pulmonary Medicine; Lung Biology. Maximum value of grant is \$32,500 US per year for up to two years. Research areas of particular interest are: Adult Pulmonary Medicine; Pediatric Pulmonary Medicine; Lung Biology. Maximum value of grant is \$32,500 US per year for up to two years.

Dalsemer Research Grant: Seed monies for investigators working in interstitial lung disease. Maximum value of grant is \$35,000 US per year for up to two years.

American Lung Association/LAM Foundation Research Grant: Seed monies for investigators with a specific focus in lymphangioleiomyomatosis research. Maximum value of grant is \$35,000 US per year for up to two years.

American Lung Association/LAM Foundation Career Investigator Award: Stable salary and/or project support for lymphangioleiomyomatosis research. Award intended for investigators making the transition from junior to mid-level faculty. Maximum value of grant is \$50,000 US per year for up to three years.

American Lung Association/Pulmonary Fibrosis Foundation Research Grant: Seed monies for investigators working in pulmonary fibrosis. Maximum value of grant is \$35,000 US per year for up to two years.

American Lung Association//LUNGeivity Research Grant: Seed monies for investigators working in the field of lung cancer. Maximum value of grant is \$35,000 US per year for up to two years.

Title: Cardiovascular Medicine Funding Opportunities
Agency: American College of Cardiology
Identification: N/A
Deadline: Various - see below
Link: <<http://www.acc.org/about/award/awardopps.htm#investigators>>

The American College of Cardiology and its industry partners provide significant financial awards to advance research in cardiovascular disease. Nominations are required for some awards, and eligibility and award vary. For more information, visit the link above or call the Member Relations Department at 800-253-4636 ext. 674.

Aug. 15, 2003: Distinguished Fellowship Award; Distinguished Service Award; Distinguished Scientist Award; Honorary Fellowship Award; International Service Award

Sept. 12, 2003: Henry I. Russek Travel Award (for NY Symposium)

Sept. 16, 2003: Young Investigators Awards Competition

Sept. 29, 2003: ACCF/Bristol-Myers Squibb Affiliate Travel Awards

Sept. 30, 2003: Pfizer/ACCF Visiting Professorship Program in Cardiovascular Medicine

Oct. 1, 2003: Career Development Awards; ACCF/Bristol-Myers Squibb Career Dev. Award; ACCF/Procter & Gamble Pharmaceuticals Career Development Award; ACCF/Pharmacia Career Development Award; ACCF/Harry B. Graf Career Development Award; ACCF/William F. Keating Career Development Award ▼

Title: American Association of Diabetes Educators (AADE) and Research Foundation Research Awards
Agency: AADE and AADE Research Foundation
Identification: N/A
Deadline: October 2, 2003
Link: <<http://www.diabeteseducator.org/AADEFoundation/Grants/Foundationindex.html>>

American Association of Diabetes Educators (AADE) Education and Research Foundation, a non-profit organization, was established in 1988 by the

members of AADE. The mission of the American Association of Diabetes Educators Education and Research Foundation is to provide or generate funding and resources to advance the role of diabetes educators, which will improve the quality of diabetes education and care.

J. K. Lilly Global Social Service Award: \$25,000 - Sponsored by Eli Lilly and Company. For the development of a program to improve diabetes education for disadvantaged and/or underserved populations in a foreign country. Principal investigator must be a current AADE member.

Eli Lilly Type 2 Diabetes in Primary Care Award: \$15,000 - Sponsored by Eli Lilly and Company. Recognizes the development, implementation and evaluation of an innovative approach to the delivery of collaborative diabetes care and education to persons with type 2 diabetes treated in a primary care setting. Proposed project must include at least one physician in a primary care practice and at least one diabetes educator who is involved in all aspects of planning and implementation.

Sigma Theta Tau Grant/AADE Foundation Grant: \$6,000 - Sponsored by the AADE Education and Research Foundation and Sigma Theta Tau International. For a research project in the field of diabetes education. Principal investigator must be a member of AADE and an RN with a Master's degree



INFECTIOUS DISEASES

Title: Mycology Research Units
Agency: National Institute of Allergy and Infectious Diseases (NIAID)
Identification: RFA: AI-03-021
Deadline: Letter of Intent Receipt Date - September 23, 2003; Application Receipt Date - October 23, 2003
Link: <<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-03-021.html>>

The National Institute of Allergy and Infectious Diseases (NIAID) invites applications for program project (P01) grants to conduct interdisciplinary research to increase understanding of the biology and host-pathogen interactions of the medically important fungi. This fundamental knowledge will be applied to the development of new and improved strategies for the prevention, diagnosis, and therapy of the mycoses. Therefore, the proposed research

must be focused on the identification and validation of targets for the development of diagnostics, vaccines or therapeutics directed against systemic mycotic infections, leading to but not including clinical trials.



Title: Partnerships for Vaccine and Diagnostic Development

Agency: National Institute of Allergy and Infectious Diseases (NIAID)

Identification: RFA: AI-03-028

Deadline: Letter of Intent Receipt Date - August 23, 2003; Application Receipt Date: September 24, 2003

Link: <<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-03-028.html>>

NIAID strives to understand, treat and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control and prevent diseases caused by virtually all infectious agents. This includes basic biomedical research, such as studies of microbial physiology and antigenic structure; applied research, including the development of diagnostic tests; and clinical trials to evaluate experimental drugs and vaccines. This Partnership program will use the cooperative agreement (U01) funding mechanism to support the development and testing of products for selected human infectious diseases of public health importance. A key component of the Partnership initiatives is the development of appropriate partnerships among government, academia, and the biotechnology, chemical or pharmaceutical industries.



Title: Integrated Preclinical/Clinical Program for Topical Microbicides

Agency: National Institute of Allergy and Infectious Diseases (NIAID) / National Institute of Child Health and Human Development (NICHD)

Identification: PAR-03-137

Deadline: Letter of Intent Dates - August 22, 2003, August 23, 2004, 2005; Application Receipt Dates: September 23, 2003, 2004, 2005

Link: <<http://grants.nih.gov/grants/guide/pa-files/PAR-03-137.html>>

NIAID and **NICHD** invite multi-project, multi-disciplinary applications (U19) whose goal is to advance safe, novel topical microbicides and microbicide combination strategies that prevent the sexual transmission of HIV, from preclinical to clinical studies. Topical microbicides are defined as vaginally or rectally applied biomedical products with or without contraceptive activity that safely inactivate HIV or prevent HIV infection or spread from initial target cells. The purpose of the Integrated Preclinical/Clinical Program for HIV Topical Microbicides (IPCP-HTM) described in this PA is: (1) to encourage discovery and preclinical development of lead topical microbicide candidates and combinations, and (2) to foster translation of safe, new microbicides/combinations from preclinical studies to pilot clinical studies. The ultimate goal of this research is the development and exploratory clinical evaluation of new and potentially effective microbicides for the prevention of HIV sexual transmission. Such research is expected to increase the array of approaches and availability of potential candidates and combinations suitable for evaluations of safety and effectiveness in human clinical studies. In line with this objective, the PA will support diverse and creative microbicides/combinations with sound scientific rationale that are new and innovative or understudied. The PA provides a continuous spectrum of research opportunities—from discovery and preclinical development to pilot clinical studies—for interdisciplinary research groups to conduct.



MISCELLANEOUS & CROSSCUTTING

Title: Research Program Awards

Agency: American Skin Association

Identification: N/A

Deadline: October 1, 2003

Link: <<http://www.skinassn.org/frameset.htm>>

The American Skin Association (ASA), founded in 1987, is the only volunteer-led health organization dedicated—through research, education and advocacy—to saving lives and alleviating human suffering caused by the full spectrum of skin disorders. Through its national grants and awards programs, the American Skin Association has distributed more than \$3 million dollars for awards,

grants, laboratories, and professorships throughout the country. The ASA's Medical/Scientific/Policy Advisory Board at its annual December meeting reviews all applications. For guidelines, call (800) 499-SKIN or e-mail to <info@americanskin.org>.

Research Scholar Awards: \$50,000 -

Purpose: To support young physician/scientists working in the field of dermatology and cutaneous biology at a time when support is critical in their career development.

Requirements: Candidates must be under the age of 40 before 6/30/04 and work full-time in a department of dermatology with a rank of instructor up through associate professor.

Research Grants: \$15,000 -

Purpose: For support of new or ongoing research/clinical investigations in Skin Cancer/Melanoma, Psoriasis, Vitiligo, Childhood Skin Diseases/Disfigurement, Pigment Cell Biology and Auto-immune Inflammatory Skin Diseases.

Requirements: Applicants working actively in the areas related to dermatology. Funds may be used for support of a new or ongoing research/clinical investigation project. No specific age requirements.

Health Services/Quality of Life/Outcome Studies Grant: \$15,000 -

Purpose: For support of research targeting Health Services/Quality of Life/Outcome Studies.

Requirements: Applicants should be working actively in the areas related to dermatology. Funds may be used for support of a new or ongoing research/clinical investigation project. No specific age requirements.




PUBLIC HEALTH & BIOTERRORISM

Title: Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense and SARS


Agency: National Institute of Allergy and Infectious Diseases (NIAID)

Identification: RFA: AI-03-017

Deadline: Letter of Intent Receipt Date - September 22, 2003; Application Receipt Date - October 22, 2003

Link: <<http://grants1.nih.gov/grants/guide/rfa-files/RFA-AI-03-017.html>>

The NIAID, using the U01 and U19 mechanisms, solicits applications for projects to develop new

products to protect the public from the health consequences resulting from the use of biological agents in acts of terrorism or war. The biological agents deemed to pose the greatest threat to civilian populations have been prioritized in the NIAID Category A, B, and C priority pathogens and toxins list <http://www.niaid.nih.gov/dmid/bioterrorism/bandc_priority.htm>. The recent emergence of SARS, its relative ease of transmission, disease severity, and potential for epidemic spread require the rapid development of interventions by the research community and the private sector. To this end, NIAID is interested in supporting the early stages of development of specific high priority products against the newly recognized SARS Coronavirus. High priority products against the SARS Coronavirus include the development of vaccines, therapeutics, and diagnostics. In response to these needs, it is imperative that promising findings are translated rapidly into new approaches and strategies for product development. The involvement of experts from diverse disciplines (e.g., biochemists, structural biologists, protein chemists, pharmacologists, immunologists, molecular biologists, engineers and clinicians) within academia and industry in early stage product development is needed to bring sufficient knowledge to bear on the development of well-designed candidates for vaccines, adjuvants, therapeutics, immunotherapeutics, and diagnostics. Applications should address research that will advance the development of a vaccine, adjuvant, therapeutic, immunotherapeutic, or diagnostic that is specific for an NIAID Category A, B, or C priority toxin, pathogen, or their arthropod vector; or the SARS Coronavirus. Research is not required to result in a "final" product but must advance the development of a candidate product. One objective of this RFA is to stimulate scientifically sound, original, and innovative research requiring comprehensive team and multidisciplinary effort that is likely to advance promising candidate products or platform technologies through the product development pathway. All applications should define the proposed project goal, interim objectives (development milestones), a general description of the potential ultimate product (a specific product profile that is defined by licensing indication is not requested), and provide a schedule or timeline for milestone and goal attainment. Projects may include, but are not limited to, one or more of the following areas: Vaccines, Adjuvants, Therapeutics, Immunotherapeutics (innate immunity, antibodies), Diagnostics, and Vector Control. 


**SPECIFIC DISEASES
& CONDITIONS**


Title: Basic Research in the Bladder and Lower Urinary Tract

Agency: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / National Institute of Aging (NIA) / Office of Research on Women's Health (ORWH)

Identification: PA-03-136

Deadline: NIH Standard receipt cycles <<http://grants1.nih.gov/grants/dates.htm>>

Link: <<http://grants.nih.gov/grants/guide/pa-files/PA-03-136.html>>

NIDDK and **NIA**, in cooperation the **ORWH**, invite applications (R01, R21) for research studies which focus on basic cellular, molecular, genetic and developmental mechanisms of the normal and abnormal function of the bladder and lower urinary tract. An important goal of this initiative is to attract new and established investigators from a variety of basic science research areas to apply their knowledge, skills, and tools to studies of the bladder and lower urinary tract. Areas of special interest include, but are not restricted to, basic cellular biology of bladder epithelial and smooth muscle cells and connective tissues; organ innervation, vascularization and physiology; genomics and proteomics, including studies of age-related changes in gene expression; development of animal models; pathogen-host interactions in infectious conditions of the bladder; and developmental biology of the lower urinary tract, including sex differences. Studies proposing the development and application of novel tools and technologies including methods of in vivo functional assessment and imaging, are encouraged. Also, basic science studies addressing sex/gender differences that may predispose women to bladder and lower urinary tract disorders are encouraged. Another important goal is to promote productive research collaborations for study of the lower urinary tract between clinicians and basic scientists. 


**TRAINING & CAREER
DEVELOPMENT**

Title: NIGMS Post-Baccalaureate Research Education Program (PREP)



Agency: National Institute of General Medical Sciences (NIGMS)

Identification: PAR-03-140

Deadline: Application Receipt Dates - October 20,

2003; October 20, 2004; October 20, 2005; October 20, 2006

Link: <<http://grants.nih.gov/grants/guide/pa-files/PA-03-140.html>>

In response to the NIH Revitalization Act of 1993, by which NIH was encouraged to increase the number of underrepresented minorities participating in biomedical and behavioral research, institutions with graduate programs and demonstrated experience in training PhD candidates in the biomedical sciences and faculty involved in biomedical research would have an opportunity to target those talented and promising minority baccalaureate graduates who, for a variety of reasons, have decided to postpone application to PhD programs. The overall goal of this initiative is to increase the number of competitively trained underrepresented minority students who enroll in and eventually complete biomedical sciences PhD programs. In addition, we hope to develop a cohort who will eventually become the scientists who conduct research on cardiovascular disease, diabetes, cancer, arthritis, respiratory diseases, HIV, and other STDs, substance abuse, and other areas that address reducing health disparities. Applicant institutions are expected to provide detailed plans (via an R25 mechanism) for the recruitment and selection criteria of PREP scholars and involvement of the scholars in any special developmental activities. In addition, the overall curriculum should strengthen the mathematical and quantitative skills needed by the scholars to eventually complete the PhD degree. Thus, the application should clearly describe how the PREP scholars would be better prepared for PhD training and how the applicant institution will evaluate the quality and success of its PREP initiative. The application should also provide information on the credentials of the proposed faculty preceptors, including their experience as mentors, current research programs and publications, and current grant support. Only one application per institution may be submitted for this PA.  

Research Swap Shop

Do you have an instrument or tool with a reasonable remaining useful life that you no longer really need in your research? Do you have a need for a research related item that you know could be just as good used as new and much more economical, if only you could find a reliable source? Would you jump at the change to cash in an under-utilized item, or trade for something you could use more? Are you looking for ways to stretch your resources? Tell us!! (All items offered "as is" and all relevant disclaimers apply!)

To list an item, call Trisha Addison at 792-0869 or email <addisont@musc.edu>. To pursue an item, please use the contact information in the ad.

Institutional Support for Research through the URC (University Research Committee)

The University provides support to strengthen the research capabilities of the faculty and to provide research training for residents interested in pursuing an academic career. Additional information and questions may be directed to the Office of Research and Sponsored Programs at 792-3838.

Deadline, Review and Funding Dates

Institutional Application	Deadline Resident Application	Interim Funding Request	Review Decision by	Funding Dates
April 1	April 15	May 1	June 15	July 1
August 1	August 15	September 1	October 15	December 15
December 1	December 15	January 2	February 15	April 1

NIH STANDARD RECEIPT DATES AND REVIEW AND AWARD CYCLES

TYPES OF APPLICATIONS

Institutional National Research Service Awards**
 All Academic Research Enhancement Awards, except those involving AIDS-related research
 New Research Grants, Conferences, and Research Career Awards.
 All Program Project and Center Grants (New & Revised)
 Interactive Research Project Grants
 Competing Continuation, Supplemental, and Revised Grants
 Individual National Research Service Awards (Standard)***
 All AIDS-Related Grants

CYCLE I

January 10
 January 25
 February 1
 February 1
 February 15
 March 1
 April 5
 May 1

CYCLE II

May 10
 May 25
 June 1
 June 1
 June 15
 July 1
 August 5
 September 1

CYCLE III

September 10
 September 25
 October 1
 October 1
 October 15
 November 1
 December 5
 January 2

Scientific Merit Review
 Advisory Council Review
 Earliest Project Start Date

June-July	Oct-Nov.	February-March
Sept-Oct	Jan-Feb	May-June
December	April	July

Please NOTE: Effective with the January 1, 2002 receipt dates, applicants must seek agreement to accept assignment from Institute/Center staff at least 6 weeks prior to the anticipated submission of any application requesting \$500,000 or more in direct costs for any year. See 10/16/2001 NIH Guide Notice.

** Several NIH Institutes and Centers use only one or two of the receipt dates for Institutional NRSA awards. Please check the program announcement for "Institutional Research Training Grants (T32)" at <<http://grants.nih.gov/training/nrsa.htm>>

*** The National Research Service Award Individual Predoctoral Fellowships for Minority Students and Students with Disabilities have special receipt dates.

Receipt Date Policy

- * An unsolicited, investigator-initiated application is considered on time if it is either (1) received by or (2) mailed on or before the published receipt date and a proof of mailing is provided. Proof of timely mailing consists of a legibly dated U.S. Postal Service postmark or a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks are not acceptable. This policy also applies to unsolicited AIDS-related applications and to AREA applications.
- * Solicited applications and proposals must be received by the specified date. However, an application received after the deadline may be acceptable if it carries a legible proof-of-mailing date assigned by the carrier and the proof-of-mailing is not later than one week prior to the deadline date. Solicited applications include those in response to Requests for Applications (RFAs); Program Announcements (PAs) with specified receipt dates (dates other than the standard ones specified in the chart below), such as Small Business Innovation Research (SBIR), and Small Business Technology Transfer (STTR); and Requests for Proposals (RFPs).
- * **Starting Nov. 13, 2001, NIH will no longer accept hand-delivered applications to the Center for Scientific Review. All applications and other deliveries to the Center for Scientific Review must either come via courier delivery or the USPS.**
- * When a receipt date falls on a weekend or holiday, the receipt date will be the following business day.

EDITORIAL STAFF

Peggy Schachte.....Editor
 Jennifer Schnellmann.....Science Editor
 Trisha Addison.....Production Manager
 Contact: addisont@musc.edu
 Phone (843) 792-5828 FAX (843) 792-1657